Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | ACLY | P53396 | 7/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | ACACB | O00763 | 1/20 | 0.47 |
| ▸ | ACACA | Q13085 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9218529 | 0.81 | LMNA (0.50) | TSHRACLYMEN1KMT2ALMNA | |
| SCHEMBL3489252 | 0.79 | MEN1 (0.54) | MAPTGAAMEN1KMT2ALMNA | |
| SCHEMBL3489106 | 0.79 | LMNA (0.57) | TSHRACLYMEN1KMT2ALMNA | |
| SCHEMBL13577033 | 0.78 | KMT2A (0.64) | NPC1TSHRMAPTMEN1KMT2A | |
| SCHEMBL12368225 | 0.77 | ACLY (0.75) | NPC1TSHRACLYACACBACACA | |
| SCHEMBL3489572 | 0.76 | PGR (0.50) | ACLYMEN1KMT2APOLBALDH1A1 | |
| SCHEMBL3489087 | 0.76 | ALDH1A1 (0.55) | MAPTGAAMEN1KMT2ALMNA | |
| SCHEMBL7586724 | 0.74 | NPC1 (0.68) | NPC1TSHRMAPTMEN1KMT2A | |
| SCHEMBL28450939 | 0.73 | MEN1 (0.68) | MAPTMEN1KMT2ALMNAHTT | |
| SCHEMBL7572911 | 0.73 | NPC1 (1.00) | NPC1TSHRMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035866-A1 | NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035866-A1 | NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | OPRD1, HTR6, HTR1D | NPC1 1533/4885TSHR 323/4885ACLY 3495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.